No. 362
Human Resources, Skills and Social Development and the Status of Persons with Disabilities
:
Mr. Speaker, the following questions will be answered today: Nos. 2905, 2907, 2909, 2910, 2914, 2916, 2918, 2919, 2925, 2929, 2931, 2932, 2934 and 2941.
[Text]
Question No. 2905—Mr. Don Davies:
With regard to budget 2024 and the government’s subsequent amendments to the Canada Student Financial Assistance Act and the Canada Student Loans Act: (a) what criteria did the government use to develop the list of health care professionals and social services professionals included in the amendments; (b) which health care professionals and social services professionals were included in the assessments in (a); (c) for each health care professional and social services professional included in the assessments but not included in the amendments, what is the rationale to exclude the professionals from the final list; (d) what is the total expected cost of the loan forgiveness measures announced in budget 2024, broken down by profession; and (e) what was the estimated cost of including occupational therapists in the loan forgiveness program?
Mr. Irek Kusmierczyk (Parliamentary Secretary to the Minister of Employment, Workforce Development and Official Languages, Lib.):
Mr. Speaker, in response to part (a) of the question, in recognition of increasing workforce shortages in the health care and social services sectors in rural and remote communities, Budget 2024 committed to expanding the list of eligible occupations for Canada Student Loan, or CSL, forgiveness to 10 new occupations: early childhood educators, dentists, dental hygienists, pharmacists, midwives, personal support workers, physiotherapists, psychologists, social workers, and teachers. This expansion will ensure all Canadians can benefit from greater access to the health and social services they need, no matter where they live.
Several factors were considered in determining the list of newly eligible professions.Labour market information (e.g., the Canadian Occupational Projection System) was used to identify sectors that are projected to be in shortage in the coming years. In addition, extensive consultations were undertaken with provinces and territories, stakeholders from numerous different professions, and student organizations to ensure their voices were heard while the Government examined various options. The need for enhanced mental health supports, the growing importance of interdisciplinary care, and care services for an aging population were all highlighted as priorities for stakeholders. Additionally, certain occupations were identified as playing key roles in supporting the implementation of Government of Canada priorities, namely the Canada-wide Early Learning and Child Care system, the Canadian Dental Care Plan, and the proposed National Pharmacare Plan. While there are numerous other occupations in shortage in rural and remote communities, fiscal consideration was also taken into account. The expansion of the list to add the additional ten new occupations balances both fiscal prudence and health and social service shortages.
With regard to part (b), a variety of occupations were examined as part of the process of assessing an expansion to the list of professionals eligible for CSL Forgiveness. This included various health and social service occupations that deliver primary care, interdisciplinary health care, and technical/supporting services.
With regard to part (c), numerous occupations are in-demand in rural and remote communities. As noted in the response to (a), several factors were considered to determine the proposed ten new occupations, including labour market information, stakeholder feedback, complementarity with other efforts to address workforce shortages in healthcare and in social services, and financial considerations.
With regard to part (d), the total cost of the loan forgiveness measure over four years, from 2025-26 to 2028-29, is $301.7 million dollars. While Budget 2024 did not provide the cost breakdown by profession, Employment and Social Development Canada officials are currently working on a Regulatory submission, which will disaggregate some of the costs.
With regard to part (e), as the profession of occupational therapists was not retained for the Budget 2024 proposal on Canada Student Loan forgiveness, no cost was estimated for the budget.
Question No. 2907—Mr. Brad Vis:
With regard to budget 2024 which stated that the changes to capital gains taxes would increase federal revenues by $19.4 billion over five years starting in 2024-25: (a) how did the government arrive at this figure; and (b) what data sources were used?
Hon. Chystia Freeland (Deputy Prime Minister and Minister of Finance, Lib.):
Mr. Speaker, in response to part (a) of the question, this figure was estimated using historical information on individual, including trust, and corporate tax filings to project capital gains realizations in future tax years, i.e. ending in 2024 through 2029, using the Department of Finance’s forecasting and simulation models.
Adjustments were made to the baseline projections of capital gains realizations to account for some filers choosing to realize capital gains prior to the effective date of June 25, 2024, leaving less capital gains in future years that would have otherwise been subject to the higher inclusion rate had they not been pulled forward.
The simulation models account for, among other things: changes in the inclusion rate on net capital gains and stock options subject to the $250,000 threshold, the inclusion rate for allowable business investment losses, adjustment factors applied to net capital losses of prior years, Alternative Minimum Tax calculations, and the value of the lifetime capital gains exemption.
In addition, it was assumed that the higher inclusion rate for corporations would result in a reduction in the capital dividend account, and a greater value of taxable dividends paid out by corporations to be taxed in the hands of individuals.
Furthermore, an adjustment factor was applied to the model output to account for additional behavioural responses to the reform, i.e. retiming of capital gains realizations across years after 2024, changes in the allocation of assets to fixed income investments.
As for part (b), the Department of Finance’s modelling tools leverage historical personal, trust and corporate income tax filing data from the Canada Revenue Agency.
The growth rates for key income variables, including capital gains and stock options, are based on the same departmental projection model that is used to forecast key fiscal and economic variables for the federal budget.
Question No. 2909—Ms. Laurel Collins:
With regard to the Assessment Framework and Guidelines that deliver on Canada’s G7 and G20 commitments to phase out or rationalize inefficient fossil fuel subsidies: (a) how many tax and non-tax measures have been assessed and met the criteria to be considered an efficient fossil fuel subsidy; and (b) for each tax and non-tax measure identified in (a), which of the six criteria identified in the framework were met?
Hon. Steven Guilbeault (Minister of Environment and Climate Change, Lib.):
Mr. Speaker, as part of its effort to fulfill Canada’s G20 commitment to phase out or rationalize inefficient fossil fuel subsidies, on July 24, 2023, the Government of Canada released the Inefficient Fossil Fuel Subsidies (IFFS) Government of Canada Self-Review Assessment Framework and the Inefficient Fossil Fuel Subsidies Government of Canada Guidelines. The Framework provides a definition of a fossil fuel subsidy and the methodology for assessing efficiency, while the Guidelines prevent the creation of any new inefficient subsidies. The Framework and Guidelines were jointly developed by Environment and Climate Change Canada and the Department of Finance Canada and apply to all federal departments and agencies.
Consistent with the Inefficient Fossil Fuel Subsidies Government of Canada Self-Review Assessment Framework, the Government of Canada has phased out or rationalized the following nine tax measures supporting the fossil fuel sector: phase-out of the accelerated capital cost allowance for oil sands (announced in Budget 2007);reduction in the deduction rates for intangible capital expenses in oil sands projects to align with rates in conventional oil and gas sector (announced in Budget 2011); phase-out of the Atlantic Investment Tax Credit for investments in the oil and gas and mining sectors (announced in Budget 2012); reduction in the deduction rate for pre-production intangible mine development expenses to align with rate for the oil and gas sector (announced in Budget 2013); phase-out of the accelerated capital cost allowance for mining (announced in Budget 2013); allowing the accelerated capital cost allowance for liquefied natural gas facilities to expire as scheduled in 2025 (announced in Budget 2016); rationalize the tax treatment of expenses for successful oil and gas exploratory drilling (announced in Budget 2017); phase out tax preference that allows small oil and gas companies to reclassify certain development expenses as more favorably treated exploration expenses (announced in Budget 2017); and, phase-out of flow-through shares for oil, gas, and coal activities (announced in Budget 2022).
Canada is currently developing a self-review report which will include information on all identified federal fossil fuel subsidies and its self-assessment against the IFFS Framework. These reports will be made public before the end of 2024.
Question No. 2910—Ms. Laurel Collins:
With regard to the pilot system for rapid heat wave attribution: (a) which heat waves have been assessed to calculate how much human-caused global warming changed the risks of such an event occurring, including during the development of the system; (b) what steps are being taken and what is the expected timeline to expand the pilot to include extreme cold weather events and extreme precipitation; and (c) are there plans to expand the pilot to include wildfires, drought, and floods?
Hon. Steven Guilbeault (Minister of Environment and Climate Change, Lib.):
Mr. Speaker, in response to part (a) of the question, the pilot heatwave attribution system is based directly on a published event attribution analysis of a heatwave which occurred in May 2023 in Alberta. Since the pilot system began running in March 2024, it has been applied to a range of moderate heatwaves in regions across Canada over the period March – June 2024. These have been used to evaluate the system, but the results have not been published.
With regard to part (b), research is going on this year to expand the system to allow attribution of cold extremes, and precipitation extremes. Applying rapid event attribution to cold extremes is a technically straightforward update to the existing system but requires research to ensure that the climate models used are able to simulate these events realistically. Attribution of precipitation extremes requires evaluation of observational datasets, and more in-depth model evaluation. We plan to include these variables in the rapid event attribution system by the end of March 2025.
With regard to part (c), Environment and Climate Change Canada has collaborated with Natural Resources Canada to carry out an event attribution study of the 2023 Canadian wildfire season which has been submitted to a scientific journal but has not yet been peer reviewed. It is anticipated that this study could be used as a basis for attribution of future extreme wildfire seasons on an expedited timeline, compared to many months for a typical analysis. Such analyses are typically applied to a whole fire season, rather than individual wildfires. Research on rapid event attribution of flooding across Canada is a part of the rapid event attribution project and it will be developed in the next two to five years. Droughts tend to be longer-term phenomena that are not as well suited to rapid attribution. We do not currently have plans to include drought in the rapid event attribution system, but attribution of drought is a subject for future research.
Much of this research is taking place at Environment and Climate Change Canada offices at the University of Victoria, in Victoria.
Question No. 2914—Mr. Chris Warkentin:
With regard to the increase to capital gains taxes announced in budget 2024: prior to the release of budget 2024, did the government consult anyone on these tax increases, and, if so, what are the details, including (i) who was consulted, (ii) how they were consulted, (iii) when they were consulted?
Hon. Chrystia Freeland (Deputy Prime Minister and Minister of Finance, Lib.):
Mr. Speaker, the Government of Canada regularly consults Canadians and stakeholders in the context of pre-budget consultations, with over 16,000 submissions and suggestions received in advance of Budget 2024.
A search of the records of the Department of Finance did not produce any results.
Question No. 2916—Mr. Dean Allison:
With regard to Health Canada's (HC) decision to approve the COVID-19 modRNA vaccines and the Prime Minister's subsequent support for the vaccine mandates in the federal public sector and vaccine passports for travel purposes during the COVID-19 pandemic: (a) what is the immunological mechanism of action of the COVID-19 mRNA vaccines that enables them to stop the spread of SARS-CoV2; (b) what data supports this mechanism of action; (c) who or what agency provided the data and verified the data; (d) when was this data provided to (i) HC, (ii) the Office of the Prime Minister; (e) what data did Pfizer and Moderna produce to HC that demonstrated (i) the period of time the spike protein is produced in the body, (ii) where in the body the spike protein is produced; and (f) in relation to (e), what was the period of time Pfizer and Moderna tracked the spike protein in their clinical studies?
Mr. Yasir Naqvi (Parliamentary Secretary to the Minister of Health, Lib.):
Mr. Speaker, the health and safety of Canadians is Health Canada’s top priority, and the department exercises stringent regulatory oversight over vaccines, including the COVID-19 vaccines. Before a vaccine is approved in Canada, the department conducts a rigorous scientific review of its safety, efficacy and quality. Submissions filed by vaccine manufacturers typically contain extensive data regarding the vaccine's safety, efficacy and quality, including results of pre-clinical and clinical studies, details on manufacturing processes, and information on adverse events following immunization. For your information, the clinical data that was submitted in support of the approval of COVID-19 vaccine by manufacturers, can be found on the Clinical Information Portal. An authorization was only issued when anticipated benefits of the vaccine outweighed the potential risks of its use.
The mRNA in the COVID-19 mRNA vaccines provides instructions for how to make the viral spike protein of SARS-CoV-2. The spike protein triggers an immune response. The body then prepares antibodies and cells that help fight the virus if it enters the body in the future. Additional details on how the COVID-19 mRNA vaccines work ca be found at COVID 19 mRNA vaccines – Canada.ca. The vaccines have demonstrated to be highly effective in prevention of COVID-19 caused by SARS-CoV-2.
Studies on the biodistribution and pharmacokinetics of the drug product were conducted and were submitted as part of the pre-clinical and early clinical trial phase data packages that companies are required to submit to regulatory agencies, including Health Canada. The pre-clinical data provided by the companies demonstrated that vaccine-produced spike protein is rapidly broken down and does not persist in the body. These data were analyzed by Health Canada prior to authorizations being granted for the COVID 19 vaccines. The outcomes of some of these studies can be found in the Summary Basis of Decision for each product, available on the COVID 19 vaccines and treatments portal.
Question No. 2918—Mr. Ted Falk:
With regard to Health Canada's (HC) review of the COVID-19 modRNA vaccine products: (a) did HC consider the specific nature of the nanotechnology of the lipid particles used for the modRNA vaccine delivery; (b) if the answer to (a) is affirmative, what was their assessment; (c) why was the fact that modRNA vaccines contain nanotechnology omitted from the product monograph-label; (d) did HC assess the toxicity of pegylated nanoparticles, specifically the risk for complement activated related pseudo allergy (CARPA) with the lipid nanoparticles used in the mRNA vaccines; (e) if the answer to (d) is affirmative, why was this not included in the product labelling; (f) if the answer to (d) is negative, why wasn't this assessed; (g) did HC assess the risk of toxicity due to the nanoformat of these vaccines; (h) if the answer to (g) is affirmative, what was the assessment result; (i) if the answer to (g) is negative, why not; (j) did HC assess the lipid nanoparticles as a novel excipient; (k) if the answer to (j) is affirmative, what was the assessment; (l) if the answer to (j) is negative, why not; (m) with respect to nanotechnology products and their unique properties and behaviors particularly in their application to the modRNA vaccines, did HC examine (i) the safety, (ii) the effectiveness, (iii) the risk to the environment, (iv) its specific regulatory status; (n) if the answers to (m)(i) to (m)(iv) is affirmative, what were the assessment results; (o) if the answers to (m)(i) through (m)(iv) is negative, why not; (p) how do established safe levels of DNA apply, (i) when using pegylated LNPs as a delivery system, (ii) when a product that contains pegylated LNPs requires repeated dosing; and (q) what assessment was performed to assess the risk of residual DNA when using pegylated LNPs as a delivery system in a vaccine which requires repeated dosing?
Mr. Yasir Naqvi (Parliamentary Secretary to the Minister of Health, Lib.):
Mr. Speaker, in response to parts (a) to (q) of the question, the health and safety of Canadians are the utmost priority for Health Canada. Health Canada has a rigorous scientific review system in place to ensure vaccines are safe and effective in preventing the diseases they target. More information on these standards and how Health Canada regulates vaccines for human use in Canada can be found at https://bit.ly/36xea3C. Once vaccines are authorized, Health Canada releases information about the vaccine, including summaries of the data considered by Health Canada. This includes non-clinical, clinical and other studies, as well as how the decision was made. This information can be found on Health Canada’s website at http://bit.ly/30LJM2z.
Studies to support the safety of the COVID-19 vaccines were conducted and were submitted as part of the pre-clinical and clinical data packages that companies are required to submit to regulatory agencies, including Health Canada. These data were analyzed by Health Canada prior to authorizations being granted for the COVID-19 vaccines.
The evaluation of toxicity of the COVID-19 mRNA vaccines was focused on the vaccines themselves, the components and the delivery system. In non-clinical studies, the toxicity of vaccines was tested either as the whole product containing the delivery system as marketed in Canada, medicinal ingredients, i.e COVID-19 antigens, or non-medicinal ingredients, including the components in the formulation.
Polyethylene glycol, or PEG, is an ingredient that is widely used in cosmetics, food products, and pharmaceuticals. Monoclonal antibodies, for example, are frequently conjugated with PEG to increase stability. Products containing PEGylated lipid nanoparticles, or LNPs, such as Onpattro, have been on the Canadian market for several years and are not unique to the COVID-19 vaccines.
In the product monograph, the composition/components contained in the vaccine, including the LNPs, are listed in the Table of “Dosage Form, Strength, Composition and Packaging”. The important data from the required toxicity tests for the vaccine product are also presented.
The manufacturing data provided to Health Canada demonstrated the ability to produce a vaccine with consistent quality. Impurities, including residual DNA, are controlled through maximum permissible limits during the manufacturing process and before the product is released on the market to ensure safety. These impurities are evaluated using validated assays, and limits are set to ensure product quality and safety. These requirements are informed by science and are aligned with international standards, including the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
More information is publicly available in the Summary Basis of Decision available on the COVID-19 Vaccines and Treatments Portal on canada.ca.
Following authorization, Canada has a robust and well-established vaccine safety surveillance system involving Health Canada, Public Health Agency of Canada, or PHAC, provinces and territories, and vaccine manufacturers. Health Canada continues to monitor the safety profile of health products once they are on the Canadian market, to help ensure that the benefits of the product continue to outweigh the risks. The safety profile of these products is monitored by reviewing safety information submitted by manufacturers as well as considering safety information from international regulators. When new safety issues are confirmed by the department, Health Canada takes action, which may include communicating new risks to Canadians and healthcare professionals or changing the recommended use of the product. In addition, Health Canada and the PHAC have been actively monitoring and reviewing reports of adverse events following immunization, or AEFI, reported to the Canada Vigilance Program of Health Canada and the Canadian Adverse Events Following Immunization Surveillance System of the PHAC. This information is published on the Government of Canada’s website. It is important to note that these reports do not necessarily imply that a relationship between the adverse event and the vaccine has been established. However, they are an important information source supporting ongoing safety monitoring.
Question No. 2919—Mr. Brad Redekopp:
With regard to the project “Board of Education of School District No. 62 (Sooke)” under Health Canada's Substance Use and Addictions Program, broken down by participating elementary, middle and secondary schools: (a) what are the names of the schools; (b) what is the cost of the curriculum, broken down by subject, which is being taught to the students; (c) what are the total number of materials that are being disseminated to the students, in total, and broken down by the names and titles of those materials; (d) broken down by schedule I, II, and III drugs and substances as defined by the Controlled Drugs and Substances Act, how much of the total funding is being allocated to each specific “primary focus” as defined by the program, broken down by each specific drug and substance; (e) how many staff or volunteers are being funded; and (f) is it a mandatory requirement for all staff or volunteers to undergo a criminal background check, and (i) have staff or volunteers been subjected to criminal background checks, (ii) have any criminal background checks for staff or volunteers turned up criminal convictions that are indictable or summary convictions, (iii) was any hired as staff or a volunteer with an indictable or summary conviction?
Mrs. Élisabeth Brière (Parliamentary Secretary to the Minister of Families, Children and Social Development and to the Minister of Mental Health and Addictions and Associate Minister of Health, Lib.):
Mr. Speaker, with regard to part (a), Health Canada, through the substance use and addictions program, or SUAP, has a contribution agreement with the board of education of schools district number 62 in Sooke. The funding is allocated to this organization and is not broken down by individual schools. According to the parameters of the agreement, funding recipients have the option to distribute a portion of their funding to other eligible third parties. Third parties are defined as individuals or entities that receive funding from the Health Canada funding recipient to carry out specific components of a project. This can include schools, with their participation at the discretion of the funding recipient.
The Health Canada funding recipient is responsible for distributing the funds and overseeing the progress of projects undertaken by any third parties. All third party funding is subject to the terms outlined in the Health Canada contribution agreement, or CA.
All funded recipients are required to account for the funds they receive from SUAP, including any amounts disbursed to third parties. They must submit a detailed budget, annual cash flow forecasts and records of expenditures on a regular basis.
With regard to parts (b), (c) and (d), the board of education of school district number 62 in Sooke is implementing a project titled “Strengthening Substance Use Prevention, Harm Reduction, and Pathways to Care in Sooke School District”. This initiative supports middle and secondary school-based events aimed at improving awareness of substance use issues among teachers in order to help them better support youth with concerning substance use behaviors and implement evidence-based drug education approaches. With SUAP funding, the organization has initiated its “Youth in Action” campaign, which includes planning and hosting health-related activities.
Curriculum development and the dissemination of materials developed for students are not central to this SUAP-funded project. Therefore, information regarding related costs and titles of materials developed for distribution to students is not available.
The recipient is not required to track or report budget expenditures categorized by substance.
The recipient holds sole responsibility for determining the focus of learning events and resources within the parameters of their school district policies and professional practice needs. School-based curriculum is supported by the B.C. Ministry of Education and managed by individual school districts. Health Canada does not direct these activities or participate in direct decision-making related to them.
To date, the project has produced and delivered 16 learning opportunities and six knowledge products in response to requests from teachers, counsellors, principals and vice-principals for easy access to evidence-aligned resources.
Two examples of initiatives implemented are as follows. One was a series of full-day, secondary school-based training events on naloxone education to 270 participating youth and staff. In addition, the project supported a forum for youth to learn more about and provide input into a regional youth strategy based on the results of the adolescent health survey available on the Sooke school website, which included a dialogue on how to reduce exposure to harms from substance use.
With regard to part (e), the project provides funding for release time of approximately 40 teachers. This allows for teachers on call to be compensated for replacing approximately 40 regular full-time teachers for a period of two days of participation in training and workshops related to the project.
With regard to part (f), the board of education of school district number 62 mandates that all employed personnel undergo and pass a criminal records check as a condition of employment. Further details about this policy can be accessed on its website.
With regard to parts (f)(i), (ii) and (iii), under their agreement with Health Canada, funded organizations are not required to report on or disclose the results of any criminal records check on their staff. However, Health Canada retains the right to request project-related information with reasonable notice at its discretion.
Question No. 2925—Mr. Dan Muys:
With regard to all infrastructure projects that have received government funding since November 4, 2015, that require the use of steel: (a) what percentage of projects used only steel produced in Canada; (b) what percentage of projects partially used steel produced in Canada; and (c) what percentage of projects used steel produced outside of Canada?
Mr. Chris Bittle (Parliamentary Secretary to the Minister of Housing, Infrastructure and Communities, Lib.):
Mr. Speaker, with regard to all infrastructure projects that have received government funding since November 4, 2015, that require the use of steel, Housing, Infrastructure and Communities Canada, or HICC, undertook an extensive preliminary search in order to determine the amount of information that would fall within the scope of the question and the amount of time that would be required to prepare a comprehensive response. The information requested is not systematically tracked in a centralized database. HICC concluded that producing and validating a comprehensive response to this question would require a manual collection of information that is not possible in the time allotted and could lead to the disclosure of incomplete and misleading information.
For more information on projects funded under HICC’s contribution programs please visit https://www.infrastructure.gc.ca/gmap-gcarte/index-eng.html and https://open.canada.ca/data/organization/infc.
Question No. 2929—Mrs. Karen Vecchio:
With regard to federally funded research for children’s illnesses: (a) how much federal funding was given out since 2015, broken down (i) year, (ii) province, (iii) illness, (iv) organization type; (b) which organizations received funding; (c) of (b), how much did each organization received, broken down by total amount (i) under $1000, (ii) $1,000 to $4,999, (iii) $5,000 to $9,999, (iv) $10 000 to $24,999, (v) $25,000 to $49,9999, (vi) $50,000 to $99,999, (vii) $100,000 to $249,999, (viii) $250,000 to $499,999, (ix) $500,000 to $999,999, (x) more than $1,000,000; (d) how many funding opportunities were available; (e) how many applications were received; (f) how many applications were accepted; (g) how much did Health Canada spend in-house; and (h) what reports were provided to the Government of Canada?
Mr. Yasir Naqvi (Parliamentary Secretary to the Minister of Health, Lib,):
Mr. Speaker, without a comprehensive list of children’s illnesses, it is not possible to determine how much Canadian Institutes of Health Research, or CIHR, funding has been allocated in this area since 2015. Additionally, CIHR has concluded that identifying projects and then producing and validating a comprehensive response to this question would require a manual collection and validation of information that is not possible in the time allotted and could lead to the disclosure of incomplete and misleading information.
All CIHR funding decisions are publicly available in the CIHR funding decisions database, available at https://webapps.cihr-irsc.gc.ca/decisions/p/main.html?lang=en#sort=namesort%20asc&start=0&rows=20
Question No. 2931—Mrs. Karen Vecchio:
With regard to the safety of novel therapeutic products approved by Health Canada (HC) through Agile Licensing: (a) does HC determine the specifications required to be completed by the manufacturer to determine a therapeutic product’s safety for use by Canadians based primarily on its (i) therapeutic indication, (ii) pharmacological mechanism of action; (b) how does HC determine that a therapeutic product is safe; (c) what clinical and pre-clinical criteria are used by HC to make a safety assessment in regards to (i) vaccines, (ii) modified mRNA products, (iii) lipid nanotechnology, (iv) medications, (v) other biologics; (d) based on the pharmacological phase of the COVID-19 vaccines (i.e. from administration to spike protein expression), (i) are adverse events following immunizations adequately detected based on the Brighton Collaboration Criteria, (ii) what are the anticipated adverse events; (e) if the answer to (d)(i) is affirmative, how has this been confirmed; (f) what specific criteria were used to confirm the COVID-19 vaccines’ safety profile at their time of (i) approval, (ii) authorization; (g) based on the requirements in (b), (c) and (f), was that information adequate to categorically declare the safety of the COVID-19 vaccines for all cohorts at the time of their (i) approval, (ii) authorization; (h) does approval of a novel therapeutic product based on the Agile Licensing pathway require criteria that are equivalent to that required under C.08.001(2) of the Food and Drug Regulations; (i) if the answer to (g) or (h) is negative, who approved the messaging from government, public health officials, and other authorities that “COVID-19 vaccines do not get approval from HC unless they are safe” or that “all vaccines authorized in Canada are safe”; (j) how has safety of the COVID-19 vaccines been re-evaluated based on detected impurities, including (i) residual DNA, (ii) residual dsRNA, (iii) SV-40 enhancer sequence, (iv) endotoxins, (v) unknown peptides resulting from frameshifting; and (k) how has safety of the COVID-19 vaccine been evaluated based on remaining excessive intracellular N1-methylpseudouridine following degradation of the synthetic modified mRNA?
Mr. Yasir Naqvi (Parliamentary Secretary to the Minister of Health, Lib,):
Mr. Speaker, with regard to parts (a) to (k), the health and safety of Canadians are Health Canada’s top priority and the department exercises stringent regulatory oversight over biologics, including vaccines. Before any of the COVID-19 vaccines were approved in Canada, the department conducted rigorous scientific review of the extensive data regarding the vaccines’ safety, efficacy and quality, including results of preclinical and clinical studies, details on manufacturing processes and information on adverse events following immunization. An authorization was only issued when the benefits of the COVID-19 vaccine outweighed the risks of its use.
For all products authorized by Health Canada, the summary basis of decision is published on the website https://dhpp.hpfb-dgpsa.ca/review-documents. This document details the clinical and preclinical data analyzed and provides a rationale for the review decision. Furthermore, as part of the regulatory requirements, a product monograph is publicly released at the time of a vaccine’s authorization. A product monograph is a factual, scientific document on the drug product that, devoid of promotional material, describes the properties, claims, indications and conditions of use for the drug, and contains any other information that may be required for optimal, safe and effective use of the drug. It is used to inform physicians, pharmacists, dentists, nurses, other health care professionals and patients about the appropriate use of the product.
The product monograph is developed and managed by the manufacturer. The content, wordings and format are carefully reviewed by Health Canada to ensure that it is prepared in accordance with the guidance. Each publicly available Canadian product monograph can be consulted by accessing the drug product database at https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html. It describes the specific evaluation methods and data used to assess safety and effectiveness for each product. As part of this assessment, Health Canada relies on clinical trials that are assessed against established international and national standards.
At the time of authorization, the safety information included in the product monograph and in package inserts is based on the available safety data from clinical trials. Furthermore, Health Canada is responsible for ensuring that the product monograph and package inserts are updated over time to adequately reflect the risks associated with the vaccines that are authorized in Canada. Health Canada-approved information is used by appropriate bodies, such as provincial and local public health authorities, to guide recommendations, vaccine use, as well as information provided to vaccine recipients. The product monograph also contains a list of adverse reactions observed during clinical trials for the product. Each drug product authorized for sale in Canada has labelling that reflects Health Canada's assessment of the product at the time of approval.
For new drug submissions, the product sponsor proposes a therapeutic indication supported by clinical trials and other data. During review of the submission, Health Canada conducts its assessment. A drug’s pharmacological mechanism of action is considered within this context. It is noted that no health product is without risks. Adverse events from the clinical trials submitted by the sponsor are carefully assessed, considered within the context of the condition treated or prevented by the product, and labelled in the product monograph, linked above.
Following authorization, Canada has a robust and well-established vaccine safety surveillance system involving Health Canada, the Public Health Agency of Canada, or PHAC, the provinces and territories, and vaccine manufacturers. Health Canada continues to monitor the safety profile of health products once they are in the Canadian market, to help ensure that the benefits of the products continue to outweigh the risks. The safety profile of these products is monitored by reviewing safety information submitted by manufacturers and by considering safety information from international regulators.
In addition, Health Canada and PHAC have been actively monitoring and reviewing reports of adverse events following immunization, or AEFIs, reported to the Canada vigilance program, or CVP, of Health Canada and the Canadian adverse events following immunization surveillance system of PHAC. Adverse events of special interest, or AESIs, which are potentially associated with vaccine products, must also be carefully monitored and confirmed by further evaluation. Information on AEFIs and AESIs is published on the Government of Canada’s website at https://health-infobase.canada.ca/covid-19/vaccine-safety/.
It is important to note that these reports do not necessarily imply that a relationship between the adverse event and the vaccine has been established. However, they are an important information source supporting ongoing safety monitoring. When new safety issues are confirmed by the department, Health Canada takes action, which may include communicating new risks to Canadians and health care professionals or changing the recommended use of the product.
The Brighton Collaboration, or BC, was established in 2001 to provide standardized, validated and objective methods for monitoring the safety profile and benefit-to-risk ratios of vaccines. This includes the development of globally implemented case definitions, guidance and protocols for data collection and comparability within and across clinical trials, surveillance systems, and post-licensure clinical studies. Health Canada has been implementing the BC criteria on case definition when assessing AEFI reports retrieved from the CVP.
Information about AEFIs reported in Canada, including the BC criteria, is published on the Government of Canada’s website at https://health-infobase.canada.ca/covid-19/vaccine-safety/.
With respect to product quality, Health Canada performs a thorough review of manufacturing processes and controls. Impurity levels in all product types are controlled by predetermined limits in place during product manufacturing and before the product is released onto the market. Health Canada ensures that scientifically justified methods are in place to monitor impurities and that the limits set are appropriate to ensure the safety of patients. The impurities are adequately controlled by the existing control system.
Agile licensing for drugs and medical devices are regulatory amendments being proposed to the food and drug regulations and the medical devices regulations. The agile regulatory proposal was pre-published in the Canada Gazette, part I, for a 130-day consultation, which closed on April 26, 2023. The proposed regulations are intended to reduce irritants and regulatory roadblocks to innovation by introducing regulations that are more agile and internationally aligned increasing postmarket oversight without compromising premarket rigour. The measures that will be introduced as part of these modernization efforts will not lessen Health Canada’s commitment to the health and safety of Canadians. The department will continue to require the same high standards of evidence about the safety, efficacy and quality of drugs and medical devices prior to authorization for sale and once on market.
Health Canada is targeting a fall 2024 Treasury Board date, with publication of the finalized regulations in the Canada Gazette, part II. As these amendments have not yet received Governor in Council approval, they are not currently considered under the regulations.
Question No. 2932—Mr. Alistair MacGregor:
With regard to the Canada Emergency Business Account, broken down by province or territory and city: how many small and medium businesses which were classified as grocery or convenience stores filed for bankruptcy after January 1, 2024?
Mr. Maninder Sidhu (Parliamentary Secretary to the Minister of Export Promotion, International Trade and Economic Development, Lib.):
Mr. Speaker, Canada emergency business account applicants are not required to provide industry information at the time of application. Therefore, bankruptcy data by industry sector is not available.
Question No. 2934—Mr. Larry Maguire:
With regard to the Canadian Armed Forces (CAF) and their involvement in the inaugural Five Eyes alliance Unidentified Aerial Phenomena caucus working group on May 24, 2023: (a) what was the agenda of the May 24, 2023 meeting; (b) what are the names and titles of all CAF personnel who attended the meeting; and (c) has the CAF participated in any other meetings of the working group and, if so, what are the dates, agenda items, and details of CAF participants at each such meeting?
Mrs. Marie-France Lalonde (Parliamentary Secretary to the Minister of National Defence, Lib.):
Mr. Speaker, as outlined in “Our North, Strong and Free”, Canada has always believed that a multilateral approach is critical to the effective delivery of the defence mandate. That is why National Defence has many partnerships on the continent and around the globe, including through the Five Eyes alliance with the United States, the United Kingdom, Australia and New Zealand.
In relation to the question above, a meeting of the Five Eyes unidentified aerial phenomena caucus working group was organized and hosted by the United States on May 24, 2023. Meeting details, including the agenda, remain under the purview of the United States.
Two officials from the Royal Canadian Airforce and the Canadian Forces Intelligence Command attended the working group meeting. National Defence applies the principles of the Access to Information Act and protects information on the grounds that disclosing certain information could be injurious to national security and defence. Therefore, further details cannot be disclosed.
Finally, in terms of any other meetings of the working group, National Defence carried out a manual search of its records within the allotted time and found no instances of further participation by members of the defence team.
Question No. 2941—Mr. Michael Barrett:
With regard to amounts collected from the federal fuel charge: (a) to date, how much has been paid by municipalities, including any municipal department or agency, broken down by province or territory, municipality and by year; and (b) how much is estimated to be paid by municipalities in the future, broken down by province or territory, municipality and year?
Hon. Chrystia Freeland (Deputy Prime Minister and Minister of Finance, Lib.):
Mr. Speaker, climate change is an existential challenge, and climate action is critical to Canada’s long term health and economic prosperity. Carbon pricing is widely recognized as the most efficient means of reducing our greenhouse gas, or GHG, emissions, which is why the Government of Canada continues to make sure that it is not free to pollute in Canada.
The federal price on pollution is revenue-neutral for the federal government; all of the direct proceeds from the federal carbon pricing system remain in the province or territory where they are collected. Put simply, every dollar collected from the carbon price is returned.
The fuel charge is generally paid at the producer or distributor level and passed on to purchasers as part of the price paid for fuel. Monthly fuel charge returns only account for aggregate amounts by fuel type and by province or territory. Typically, once the fuel charge has been paid by a fuel producer or distributor, there is no further reporting of who ultimately bears the cost of the federal fuel charge.
In the provinces where the fuel charge applies, the majority of households receive more with the Canada carbon rebate than they incur in carbon pricing-related costs. The government reports the direct fuel charge proceeds collected and returned annually through the Greenhouse Gas Pollution Pricing Act annual report. For more information on the proceeds collected and returned, please see the annual report for 2022 at the following website: https://publications.gc.ca/site/eng/9.893583/publication.html.
:
Mr. Speaker, if the government's responses to Questions Nos. 2906, 2908, 2911 to 2913, 2915, 2917, 2920 to 2924, 2926 to 2928, 2933, 2935 to 2940, and 2942 to 2946 could be made orders for return, these returns would be tabled in an electronic format immediately.
Some hon. members: Agreed.
[Text]
Question No. 2906—Mr. Brad Vis:
With regard to the National Trade Corridors Fund (NTCF): (a) under the “National Call to Address Capacity Constraints” first call for proposals in July 2017, how many projects were approved for British Columbia; (b) under the “Continuous call for Trade Diversification” launched on January 15, 2019, how many projects were approved for British Columbia; (c) under the “lncreasing the Fluidity of Canada's Supply Chains” launched on December 9, 2021, how many projects were approved for British Columbia; (d) under the “Relieving Supply Chain Congestion at Canadian Ports” launched on January 31, 2022, how many projects were approved for British Columbia; (e) under the “Advancing Supply Chain Digitalization” launched on February 13, 2023, how many projects were approved for British Columbia; (f) what is the current status of every NTCF funded project in British Columbia; and (g) how much program spending has been done each year since 2017-18?
(Return tabled)
Question No. 2908—Mr. Brad Vis:
With regard to changes in capital gains taxes as announced in budget 2024: after removing capital gains income from the calculation of total personal income, what is the share of capital gains tax revenue collected from those earning (i) equal or less than $50,000, (ii) between $50,001 and $100,000, (iii) between $100,001 and $150,000, (iv) over $150,000?
(Return tabled)
Question No. 2911—Ms. Laurel Collins:
With regard to the 2 Billion Trees Commitment, broken down by province or territory since its inception: (a) what is the total amount of funding allocated under each of the (i) cost-sharing agreements with provinces and territories, (ii) Privates Lands stream, (iii) Urban Lands stream, (iv) Federal Lands stream, (v) distinctions based Indigenous stream; (b) what is the total amount of funding delivered under each of the (i) cost-sharing agreements with provinces and territories, (ii) Privates Lands stream, (iii) Urban Lands stream, (iv) Federal Lands stream, (v) distinctions based Indigenous stream; and (c) what is the total amount of funding on hold or undelivered under each of the (i) cost-sharing agreements with provinces and territories, (ii) Privates Lands stream, (iii) Urban Lands stream, (iv) Federal Lands stream, (v) distinctions based Indigenous stream?
(Return tabled)
Question No. 2912—Ms. Laurel Collins:
With regard to species listed under the Species at Risk Act since October 2015, broken down by status (i.e. extirpated, endangered, threatened and special concern): (a) how many recovery strategies or management plans were (i) produced within the timelines set out in the act, (ii) overdue; (b) how many action plans required to support the implementation of recovery strategies were (i) produced within the timelines set out in the act, (ii) overdue; (c) how many species do not yet have recovery strategies or management plans; and (d) how many recovery strategies do not yet have action plans?
(Return tabled)
Question No. 2913—Mr. Chris Warkentin:
With regard to contracts between any government department, agency, Crown corporation, or other government entity and Speakers Spotlight, since November 4, 2015: what are the details of each contract, including the (i) date of event associated with the contract, (ii) amount, (iii) name of the speaker, (iv) event description and purpose of the speech?
(Return tabled)
Question No. 2915—Mr. Mel Arnold:
With regard to the terms of the Pacific Salmon Commercial Licence Retirement Program (LRP) under the Pacific Salmon Strategy Initiative (PSSI), broken down by each harvest area: (a) how many individual commercial salmon licenses have been retired each year broken down by gear type; (b) what were the average prices paid; and (c) what were the highest and lowest prices?
(Return tabled)
Question No. 2917—Mr. Ted Falk:
With regard to Health Canada's (HC) establishing the safety of the Pfizer/BioNTech COVID-19 vaccine in 12-15 year olds: (a) what serious adverse events (SAEs) did the pharmaceutical company disclose to Canada's health agencies for this age group pre-authorization; (b) since approving the product in this age group, has the Public Health Agency of Canada (PHAC), the National Advisory Committee on lmmunization (NACI) or HC become aware of additional adverse events (AEs) or SAEs that the pharmaceutical company had not disclosed during the initial authorization process; (c) if the answer to (b) is affirmative, (i) what AEs and SAEs has the PHAC, the NACI and HC become aware of, (ii) when were they discovered, (iii) what are the means by which Canada's health agencies were provided this information; (d) prior to authorizing this product in this age group, was the PHAC, HC or the NACI given information about (i) the SAEs of a 12-year-old trial participant named Maddie de Geray who was diagnosed with chronic inflammatory demyelinating polyneuropathy which rendered her reliant on a wheelchair and feeding tube, (ii) any other specific SAE cases in this cohort following the Pfizer inoculation; (e) if the answer to (d) is affirmative, what was the date and means by which the PHAC, the NACI or HC became aware of these cases; (f) if the answer to (d) is negative, has Ms. De Geray's diagnoses been added to HC's list of SAEs on the HC website in this age group; (g) has the PHAC, HC or the NACI been aware that the adverse events experienced by trial participant Maddie de Geray were not properly disclosed within their trial studies as described in the scientific publication of said trial (i.e. NEJM - Frenck et al. 2021); (h) did the PHAC, HC or the NACI take any action after discovering the lack of proper disclosure of Maddie de Geray's SAEs by Pfizer; (i) what was the age stratified risk-benefit analysis for 12-15 year olds in relation to the Pfizer/BioNTech COVID-19 vaccine at the time of authorization, on May 5, 2021; (j) what was the data and calculations for quantifying the risks and benefits that Canadian health agencies used to authorize or approve the product in this age group; (k) what data indicated that the benefits of the vaccine outweighed the risks at the time of authorization; (l) since the roll-out of the Pfizer/BioNTech COVID-19 vaccine in this age group, (i) what are the top ten SAEs identified in this cohort, (ii) how have these SAEs been communicated to the medical community and the public at large; (m) what type and frequency of SAEs in 12-15-year-old would invoke an unfavourable benefits-risk ratio for healthy children and for children with underlying medical conditions; and (n) is HC, the PHAC or the NACI aware of any other jurisdictions worldwide that no longer recommends the mRNA COVID-19 vaccines in children at (i) six months of age, (ii) between six months and two years (iii) between two to five years, (iv) between five to 12 years, (v) between 12-15 year, (vi) between 15-18 years?
(Return tabled)
Question No. 2920—Mr. Brad Redekopp:
With regard to a Statistics Canada report titled “Police-reported crime statistics in Canada, 2022”, The Daily — Police-reported crime statistics in Canada, 2022, and the report that there has been a 43% increase in the rates of level 1, 2, and 3 sexual assaults between 2015 and 2022: (a) does Public Safety Canada acknowledge that level 1, 2, and 3 sexual assaults have increased 43% in that time period, and, if not, why not; (b) when did Public Safety Canada learn of the 43% increase in the rates of level 1, 2, and 3 sexual assaults; (c) how long was the delay between Public Safety Canada learning of the 43% increase and the establishment of mitigation measures to reduce the number of level 1, 2, and 3 sexual assaults, broken down by the dates the measures were undertaken by Public Safety Canada and its public safety partner agencies; (d) has Public Safety Canada and its public safety partner agencies taken measures to mitigate this increase of level 1, 2, and 3 sexual assaults broken down by specific measures, including the funds allocated and spent by each specific mitigation measures?
(Return tabled)
Question No. 2921—Mr. Brian Masse:
With regard to the Canada Border Services Agency's (CBSA) Request for Assistance Program (RFA), which has historically been an effective tool for Intellectual Property (IP) rights owners to prevent counterfeit goods from crossing the Canadian border and entering the commerce stream, and having cut the RFA program significantly: (a) does the government have plans to (i) reassess the cuts to training and processes that limit CBSA officers from efficiently searching, identifying and detaining the counterfeit products, (ii) reinvest in the RFA program in the next years, and, if so, when, (iii) work and discuss the impacts that these cuts have had on Canadians, businesses and trade noting that Canada is the only G7 country on the 2023 United States Trade Representative Watchlist, (iv) meet directly with the Customs Immigration Union to ensure that the frontline officers participate in the process to reestablish increased searches, identification and counterfeit products processes; and (b) how much estimated value has been confiscated each year from this program and from how many seizures for the last ten years at all ports of entry to Canada?
(Return tabled)
Question No. 2922—Mr. Brian Masse:
With regard to the federal target of achieving 100% Zero Emission Vehicle (ZEV) market share in Canada by 2035: (a) what is the government doing now, and what was done to date to address the lack of available public charging stations throughout the country to meet the demand for ZEVs; (b) what is the number of current public charging stations available through Canada, including locations, number, and types of chargers; (c) what is the projected number of public charging stations needed to meet demand by 2035; (d) did the government consider or have plans to increase the amount of the federal Incentives for Zero-Emission Vehicles Program (iZEV) from $5000; (e) did the government consider or have plans to match the United States’ federal incentive program to provide an equal and fair incentive for purchasing domestic vehicles; (f) did the government consider a plan for federal incentives for consumer purchases of used electric vehicles to help drive the sales and meet the environmental targets; (g) is the government tracking the import and export of new and used electric vehicles, and, if so, is it starting from the year 2022; and (h) is the government tracking the movement of electric vehicles purchased in one province the later moved to another province?
(Return tabled)
Question No. 2923—Mr. Brian Masse:
With regard to the proposed deep geologic repository (DGR) plan by the Nuclear Waste Management Organization (NWMO) which could be located in South Bruce, Ontario: (a) should this site be selected, which falls within the Great Lakes basin, has the government (i) met with members of the United States Congress and United States Senate, or with our Canadian Ambassador to the United States, to hear the American concerns and opposition about storage of nuclear waste near, or within, the Great Lakes Basin, and, if so, who did they meet with, where were the meetings held and when, (ii) followed the progress of Amendment #947 to the to the FY 25 National Defense Authorization Act in U.S. Congress which calls for both Canada and the United States to not develop facilities to permanently store nuclear waste in the Great Lakes Basin and which has now moved to the United States Senate for further action and support, (iii) discussed with the NWMO alternatives to transporting and storing radioactive waste in the Great Lakes basin, (iv) considered alternatives to DGRs, such as recycling the radioactive waste, such as France, Japan, Germany and Belgium; (b) has the Prime Minister, the Minister of Export Promotion, International Trade and Economic Development or the Minister of Innovation, Science and Industry raised or responded to this issue to the President or other representative of the Biden Administration, and, if so, when and where did the meetings take place and with who?
(Return tabled)
Question No. 2924—Mr. Dan Muys:
With regard to VIA HFR – Dedicated Project Office 2023-2024 Operating Budget: (a) for each individual paid under “Technical Office: specialized individuals hired under contractual agreements”, (i) what was the average payment, (ii) what was the highest amount of payment, (iii) how many unique individuals received payment; and (b) what are the details of all entities paid under “Technical Office: Engineering, accounting, procurement, legal, technical and communication services”, including the (i) date of the payment, (ii) date signed, (iii) value, (iv) detailed description of the service(s) provided, (v) start and end dates of work, (vi) details on how the contract was awarded (sole-sourced, competitive bid), (vii) titles of the officials who approved or signed off on the contract?
(Return tabled)
Question No. 2926—Mr. Dan Muys:
With regard to the federal carbon tax collected from the transportation sector, since April 1, 2019, broken down by year: (a) what were the amounts collected from Canadian Airports; (b) what were the amounts collected from (i) Canadian Airlines, (ii) non-Canadian Airlines; (c) what were the amounts collected from Canadian ports; (d) what were the amounts collected from (i) Canadian Maritime Transportation Companies, (ii) non-Canadian Maritime Transportation Companies; (e) what were the amounts collected from (i) Canadian trucking companies, (ii) non-Canadian trucking companies?
(Return tabled)
Question No. 2927—Mr. Dan Muys:
With regard to the 21 privately-operated airport authorities in Canada: (a) what were the amount of rents collected from each airport authority since January 1, 2016, broken down by year; (b) what were the amounts of other fees or penalties collected from each airport authority since January 1, 2016, broken down by year, in total, and broken down by type of fee or penalty; and (c) since January 1, 2016, broken down by year, (i) how many projects at the 21 airports received funding by the federal government, (ii) what was the amount of funding received, broken down by project?
(Return tabled)
Question No. 2928—Mrs. Karen Vecchio:
With regard to carbon pricing on government administration, including the Carbon Tax and the Carbon Rebate, since January 1, 2019: (a) how much did the Government of Canada collect in each riding and province during each calendar year in carbon tax, broken down by (i) federal administration, (ii) provincial administration, (iii) municipal administration; (b) how much did the Government of Canada return in each riding and province during each calendar year through the Carbon Rebate, broken down by (i) federal administration, (ii) provincial administration, (iii) municipal administration; (c) of (a)(i) and (b)(i), what is the breakdown of the movement of funds from (i) central agencies, (ii) ministerial departments, (iii) separate agencies with direct ministerial oversight, (iv) independent agencies and offices, (v) independent review bodies, (vi) branches of the Canadian Armed Forces, (vii) the Senate of Canada, (viii) the House of Commons, (ix) federal courts, (x) special operating agencies, (xi) Crown corporations, (xii) Canadian Coast guard auxiliary, (xiii) federal infrastructure projects; (d) of (a)(ii) and (b)(ii), what is the breakdown of the movement of funds from (i) provincial agencies, (ii) ministerial departments, (iii) separate agencies with direct ministerial oversight, (iv) independent agencies and offices, (v) independent review bodies, (vi) provincial legislatures, (vii) provincial courts, (viii) special operating agencies, (ix) Crown corporations, (x) provincial courts, (xi) school boards and school divisions, (xii) health authorities, (xiii) public post-secondary institutions, (xiv) provincial infrastructure projects; and (e) of (a)(iii) and (b)(iii), what is the breakdown of the movement of funds from (i) municipal administration, (ii) museums and art galleries, (iii) curling rinks, (iv) hockey arenas, (v) pools, (vi) recreational centres, (vii) stadiums, (viii) community centres, (ix) municipal infrastructure projects, (x) visitor centres, (xi) homeless shelters, (xii) parks, (xiii) emergency response, (xiv) enforcement services?
(Return tabled)
Question No. 2933—Ms. Jenny Kwan:
With regard to the inventory of immigration applications in the Humanitarian and Compassionate (H&C) and other categories: (a) in which month and year were applications received, broken down by country of origin; (b) what is the average processing time from application submission to final decision, broken down by country of origin; (c) what are the total resources or staffing levels dedicated to processing applications in the H&C and other categories over the past three years to date; (d) considering that the 2024-26 Immigration Levels Plan target presently provides for a target of 29,750 allocations for the H&C and other categories in total from 2024 to 2026, with a low range of 22,000 and a high range of 41,500, and the current inventory already exceeds 70,000 applications, how many years does the department estimate it will take to clear the present application inventory without projecting for forthcoming applications; (e) what are the details of all special measures and policies included in the H&C and other categories over the last five years, including the (i) eligibility requirements for those immigration streams, (ii) descriptions of all processing prioritization directives given for each stream, (iii) dates on which updates or changes were made to those directives, broken down by country and the year the measure or policy came into effect; and (f) what plans or strategies are being developed to address the backlog of applications in these categories and to improve processing times?
(Return tabled)
Question No. 2935—Mr. Simon-Pierre Savard-Tremblay:
With regard to destroyed goods for which a “drawback” (i.e., refund) was obtained for the duties and excise taxes paid, under the Obsolete or Surplus Goods Program of the Canada Border Services Agency, broken down by year since the program was created: (a) how many refunds have been granted for goods deemed obsolete or surplus by importers, producers, manufacturers and owners, respectively; and (b) what are the details of each case, including (i) the date of the refund, (ii) the description of the goods including their respective quantities, (iii) their declared values, (iv) the amount of drawback granted, (v) the name and municipality of the recipient?
(Return tabled)
Question No. 2936—Mr. Simon-Pierre Savard-Tremblay:
With regard to federal spending in the riding of Saint-Hyacinthe—Bagot, for each fiscal year since 2020–21, inclusively: what are the details of grants and contributions and of all loans made to any organization, group, company or municipality, broken down by the (i) name of the recipient, (ii) municipality of the recipient, (iii) date on which the funding was received, (iv) amount received, (v) department or agency that provided the funding, (vi) program under which the grant, contribution or loan was made, (vii) nature or purpose of the funding?
(Return tabled)
Question No. 2937—Mr. Simon-Pierre Savard-Tremblay:
With regard to federal spending in the riding of Papineau, for each fiscal year since 2020–21, inclusively: what are the details of grants and contributions and of all loans made to any organization, group, company or municipality, broken down by the (i) name of the recipient, (ii) municipality of the recipient, (iii) date on which the funding was received, (iv) amount received, (v) department or agency that provided the funding, (vi) program under which the grant, contribution or loan was made, (vii) nature or purpose of the funding?
(Return tabled)
Question No. 2938—Mr. Simon-Pierre Savard-Tremblay:
With regard to the information revealed in the “Blood Gold Report,” which indicates that the Russian economy benefits from mining in Africa to the tune of $3.4 billion dollars Canadian, thanks in particular to the involvement of the Wagner Group, a private military company financed by the Russian state, as well as the activities of Canadian mining companies in Africa: (a) what information has the government received on the activities of two Canadian mining companies, Barrick Gold and B2Gold, operating under the Malian military regime, in connection with these revelations; (b) has the government contacted Barrick Gold or B2Gold on this subject, or does it plan to do so; (c) has the Canadian government assessed the national security implications associated with the fact that these two Canadian mining companies have made tax payments of $1.8 billion to the Russian-backed Malian regime since 2022, and are thus indirectly financing Russia’s war effort in Ukraine; (d) are there or will there be any measures, economic or otherwise, in place to prevent Canadian mining companies from indirectly financing Russia’s war effort in Ukraine; (e) are there or will there be any measures, economic or otherwise, in place with the Malian regime to make it impossible for Canadian companies to do business with the Russian state’s trading partners, including the Wagner Group; (f) how much has Canada provided to these two mining companies in grants, contributions and loans for each year since fiscal year 2019, inclusively; and (g) how much have these two mining companies paid in taxes to Canada for each year since fiscal year 2019, inclusively?
(Return tabled)
Question No. 2939—Mr. James Bezan:
With regard to the Minister of Public Services and Procurement, between January 1, 2016, and September 16, 2024, broken down by year: how many certificates of exemption from registration under the Controlled Goods Regulations were granted to or on behalf of (i) visitors from China, Russia, Iran, and North Korea within academia, government, and industry, (ii) temporary workers from China, Russia, Iran, and North Korea within academia, government, and industry, (iii) international students from China, Russia, Iran, and North Korea within academia, government, and industry?
(Return tabled)
Question No. 2940—Mr. Michael Barrett:
With regard to ministers’ and government entities’ compliance with paragraphs 74(d) and 88(c) of the Access to Information Act: (a) has each minister or government entity, subject to those provisions of the Act, complied with the requirement to disclose proactively the briefing materials prepared for each parliamentary committee appearance; (b) what is the average period of time, broken down by minister or government institution, between a parliamentary committee appearance and the proactive disclosure of the briefing materials prepared for the appearance; (c) if (a) is negative, (i) why is the minister or government entity not in compliance with the law, (ii) what is being done to bring the minister or government entity into compliance with the law; (d) which parliamentary committee appearances, subject to those provisions of the Act, during the 43rd Parliament, have outstanding requirements to disclose proactively the briefing materials which were prepared and, broken down by outstanding requirement, (i) when is proactive disclosure expected to occur, (ii) what accounts for the delay; (e) which parliamentary committee appearances, subject to those provisions of the Act, during the 44th Parliament and up to May 10, 2024, have outstanding requirements to disclose proactively the briefing materials which were prepared and, broken down by outstanding requirement, (i) when is proactive disclosure expected to occur, (ii) what accounts for the delay; and (f) which officials are considered to be persons in “a position of equivalent rank” to deputy heads for the purposes of paragraph 88(c) of the Act?
(Return tabled)
Question No. 2942—Mr. Larry Brock:
With regard to the government’s claim that it will build 250,000 new homes by 2031 as part of the Public Lands for Homes Plan: (a) how many homes have been built on the land involved in this plan; (b) how many homes are currently under development on the land involved in this plan; and (c) when was the disposal process started for each property, broken down by location?
(Return tabled)
Question No. 2943—Mr. Larry Brock:
With regard to the government’s Firearms Buyback Program: (a) how much has been spent to date on the program, broken down by fiscal year; (b) of the amount spent in (a), how much was for (i) program administration, (ii) payments to buy back firearms; (c) how much money went, or will go, towards the buyback program from the (i) allocated, (ii) unallocated, sums outlined in budget 2024; (d) when is the program expected to conclude; and (e) what is the expected total cost of the program through conclusion, broken down by expected administrative costs and expected firearm payment costs?
(Return tabled)
Question No. 2944—Mrs. Stephanie Kusie:
With regard to federal infrastructure funding being provided to either cities or provinces, where the ultimate recipient is a municipality with a population of more than 50,000 people: (a) how much funding has been provided, broken down by municipality, year, and program, since January 1, 2016; and (b) how much funding is currently budgeted to be provided in the future, broken down by municipality, year, and program?
(Return tabled)
Question No. 2945—Mrs. Stephanie Kusie:
With regard to the government’s public lands mapping tool, announced in August 2024: (a) what are the costs related to the tool, in total and broken down by type of expenditure; and (b) what are the details of all contracts over $1,000 signed by the government related to the tool, including, for each, the (i) value, (ii) date and duration, (iii) vendor, (iv) description of goods or services provided, (v) manner in which the contract was awarded (sole-sourced or competitive bid)?
(Return tabled)
Question No. 2946—Mr. Dan Albas:
With regard to the Canada Revenue Agency: (a) for the Income Tax Act, what was the total number of notices of objection filed from January 1 until August 31, 2024; (b) of the objections in (a), how many were determined in favour of the tax payer; (c) under the Income Tax Act, what seven sections received the most notices of objection from January 1 to August 31, 2024; (d) for the Excise Tax Act or the Goods and Services Tax, what was the total number of notices of objection filed from January 1 until August 31, 2024; (e) of the objections in (d), how many were determined in favour of the tax payer; (f) under the Excise Tax Act, what were the seven sections that received the most notices of objection from January 1 to August 31, 2024; (g) what is the breakdown of (a) through (f) for the (i) Atlantic, (ii) Quebec, (iii) Ontario, (iv) Western, tax centres; (h) what is the estimated number of hours and related salary costs associated with treating all of the above notices of objection that were ruled in favour of the taxpayers, in total and broken down by tax centre; and (i) for all of the tax centres across Canada, how many filings to the Tax Court of Canada were ruled in favour of the tax payer and what was the total number of filings to the Tax Court of Canada?
(Return tabled)
[English]
:
Mr. Speaker, I would ask that all remaining questions be allowed to stand.
Some hon. members: Agreed.
:
Mr. Speaker, on a point of order, I would ask for unanimous consent to present petitions.
Some hon. members: Agreed.
Human Resources, Skills and Social Development and the Status of Persons with Disabilities